Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors.
Haffner
S M
SM
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology / Q000517:prevention & control*; D005387:Finland / Q000453:epidemiology; D005951:Glucose Tolerance Test; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D015994:Incidence; D008019:Life Style; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D017035:Pravastatin / Q000627:therapeutic use; D012307:Risk Factors; D012606:Scotland / Q000453:epidemiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D008687:Metformin; D017035:Pravastatin